Rhinosinusitis with Nasal Polyps

• EMA approval · 2026-08-18
  EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie

  The EMA has authorised Dupixent (dupilumab) for multiple indications including atopic dermatitis, prurigo, esophageal diseases, asthma, and …

• EMA approval · 2026-04-20
  EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie

  The EMA authorised Dupixent (dupilumab) for multiple EU indications, including atopic dermatitis, prurigo nodularis, eosinophilic esophagiti…

• FDA approval · 2024-09-12
  FDA Approved: DUPIXENT — Supplemental Application (sanofi-aventis U.S. LLC)

  FDA approved a supplemental application for Dupixent (dupilumab) submitted by sanofi-aventis U.S. LLC.

• FDA approval · 2024-01-25
  FDA Approved: DUPIXENT — Supplemental Application (sanofi-aventis U.S. LLC)

  FDA approved a supplemental application for Dupixent (dupilumab) filed by Sanofi‑Aventis U.S. LLC, indicating an approval of a supplement re…

• FDA approval · 2023-01-20
  FDA Approved: SINUVA — Supplemental Application (Intersect ENT, Inc.)

  FDA approved a supplemental application for SINUVA (mometasone furoate) from Intersect ENT, Inc., updating its label.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2020-04-28
  FDA Approved: SINUVA — Supplemental Application (Intersect ENT, Inc.)

  FDA approves a supplemental application for SINUVA (mometasone furoate) from Intersect ENT, Inc., a steroid-releasing sinus implant used aft…

• FDA approval · 2018-10-19
  FDA Approved: DUPIXENT — Supplemental Application (sanofi-aventis U.S. LLC)

  FDA approved a supplemental application for DUPIXENT (dupilumab) submitted by Sanofi-Aventis U.S. LLC.

• FDA approval · 2018-03-19
  FDA Approved: XHANCE — Supplemental Application (OptiNose US, Inc.)

  FDA approved a supplemental application for XHANCE (fluticasone propionate) submitted by OptiNose US, Inc. The approval is categorized as a …

• FDA approval · 2017-12-08
  FDA Approved: SINUVA — Original Application (Intersect ENT, Inc.)

  FDA approved SINUVA (mometasone furoate) from Intersect ENT as a drug-eluting implant to treat chronic rhinosinusitis with nasal polyps in a…

• FDA approval · 2015-06-03
  FDA Approved: BUDESONIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

  The FDA approved a supplemental application for budesonide submitted by Teva Pharmaceuticals USA, Inc.